Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Oncology · Hepatocellular Carcinoma

Navigating Your Stage: The BCLC System

At a Glance

The BCLC staging system is the primary tool used to stage hepatocellular carcinoma (HCC). It determines your treatment path by combining three critical factors: the size and spread of the tumors, your underlying liver function, and your physical ability to perform daily activities.

Staging is the process of determining the extent of your cancer and how well your body can tolerate treatment. In Hepatocellular Carcinoma (HCC), this is uniquely complex because the health of your liver is just as important as the size of the tumor [1].

The BCLC Staging System

The most widely used tool for organizing HCC care is the Barcelona Clinic Liver Cancer (BCLC) system. Unlike other cancer staging systems that only look at the tumor, BCLC integrates three critical factors [2]:

  1. Tumor Burden: The size and number of tumors, and whether the cancer has spread into blood vessels or other organs [1].
  2. Liver Function: Measured by tools like the Child-Pugh score or the ALBI grade (which uses Albumin and Bilirubin levels). These scores tell doctors if your liver is strong enough to handle surgery or chemotherapy [3][4].
  3. Performance Status: A measure of how well you can perform daily activities (often called an ECOG score). For instance, a “good” status means you can work and be active, while a “poor” status means you spend most of your day resting in bed.

The Five BCLC Stages

The BCLC system categorizes patients into five groups, each with a primary treatment pathway:

Stage Description Typical Treatment Path
0 (Very Early) One small tumor (<2cm) and excellent liver function. Resection (surgical removal) or Ablation (heat/cold treatment) [1].
A (Early) One tumor or up to 3 small tumors; good liver function. Resection, Liver Transplant, or Ablation [1].
B (Intermediate) Multiple tumors limited to the liver; good liver function. TACE (chemotherapy delivered directly to the liver) or systemic therapy [5][6].
C (Advanced) Cancer has spread to blood vessels or lymph nodes, or the patient has a lower performance status (spending more time resting). Systemic Therapy (such as immunotherapy combinations) [7][8].
D (End-Stage) Severe liver failure or the patient is very weak and bedbound. Best Supportive Care focused on comfort and symptom management [1].

Note on Supportive Care: While Best Supportive Care (Palliative Care) is the primary path for Stage D, it should be integrated into all stages alongside active treatment. Palliative care teams help manage pain, fatigue, and side effects from day one, improving your quality of life during treatment.

Understanding HCC Subtypes

While “HCC” is the general name, tumors can look different under a microscope. These histological variants (subtypes) can sometimes predict how the cancer might behave [9]. Your doctor will discuss if your specific tumor looks like a variant that requires a slightly different approach or closer monitoring.

Moving Between Stages

The BCLC system is a guide, but modern medicine is becoming more flexible. For example, some patients in Stage B can be “downstaged” (shrinking the tumor with locoregional treatments) until they qualify for a curative liver transplant [10][11]. This “multidisciplinary” approach ensures that treatment is tailored to the individual rather than just the stage [12].

Common questions in this guide

What is the BCLC staging system for liver cancer?
The Barcelona Clinic Liver Cancer (BCLC) system is a staging tool used specifically for hepatocellular carcinoma. Unlike other cancer staging systems, it evaluates the size and number of tumors, your overall liver function, and your physical energy levels to determine the best treatment.
How does my liver health affect my cancer treatment?
In hepatocellular carcinoma, treatments can be hard on the liver. Doctors use tools like the Child-Pugh score and ALBI grade to measure albumin and bilirubin levels, ensuring your liver is strong enough to safely handle options like surgery or systemic therapy.
What does my ECOG Performance Status mean for my HCC stage?
Your ECOG Performance Status measures how well you can perform daily activities, such as working or resting in bed. It is a critical part of the BCLC staging system because it helps doctors understand how well your body can tolerate certain cancer treatments.
What does downstaging mean in liver cancer?
Downstaging involves using localized treatments to shrink liver tumors in patients who have intermediate-stage cancer. If the tumors shrink enough, a patient may move to an earlier stage and become eligible for a curative liver transplant.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my BCLC stage, and how did you calculate my Child-Pugh and ALBI scores?
  2. 2.What is my ECOG Performance Status, and how does it influence my stage?
  3. 3.If I am in the intermediate stage (BCLC-B), am I a candidate for 'downstaging' to eventually qualify for a liver transplant?
  4. 4.How does my liver's underlying health (cirrhosis) limit which cancer treatments I can safely receive?
  5. 5.Can we involve a supportive care team alongside my treatment to help manage symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.

    Jasirwan COM, Hasan I, Sulaiman AS, et al.

    Current problems in cancer 2020; (44(1)):100480 doi:10.1016/j.currproblcancer.2019.05.003.

    PMID: 31130257
  2. 2

    Application of Machine Learning Techniques to Assess Alpha-Fetoprotein at Diagnosis of Hepatocellular Carcinoma.

    Gil-Rojas S, Suárez M, Martínez-Blanco P, et al.

    International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25041996.

    PMID: 38396674
  3. 3

    Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases.

    Feng D, Wang M, Hu J, et al.

    Annals of translational medicine 2020; (8(8)):553 doi:10.21037/atm.2020.02.116.

    PMID: 32411776
  4. 4

    Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

    Marasco G, Colecchia A, Bacchi Reggiani ML, et al.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2021; (53(8)):1011-1019 doi:10.1016/j.dld.2020.12.001.

    PMID: 33353858
  5. 5

    Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

    Pecorelli A, Lenzi B, Gramenzi A, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2017; (37(3)):423-433 doi:10.1111/liv.13242.

    PMID: 27566596
  6. 6

    Recent advances in the surgical management of hepatocellular carcinoma.

    Glantzounis GK, Karampa A, Peristeri DV, et al.

    Annals of gastroenterology 2021; (34(4)):453-465 doi:10.20524/aog.2021.0632.

    PMID: 34276183
  7. 7

    Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

    Finn RS, Qin S, Ikeda M, et al.

    The New England journal of medicine 2020; (382(20)):1894-1905 doi:10.1056/NEJMoa1915745.

    PMID: 32402160
  8. 8

    Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy.

    Hatanaka T, Yata Y, Naganuma A, Kakizaki S

    Cancers 2023; (15(6)) doi:10.3390/cancers15061798.

    PMID: 36980684
  9. 9

    Chronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020.

    Tsuzaki J, Ueno A, Masugi Y, et al.

    Japanese journal of clinical oncology 2025; (55(4)):362-371 doi:10.1093/jjco/hyae187.

    PMID: 39775861
  10. 10

    Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria.

    Shi F, Lian S, Mai Q, et al.

    European radiology 2020; (30(5)):2454-2462 doi:10.1007/s00330-019-06604-y.

    PMID: 32002636
  11. 11

    Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study.

    Bartolini I, Nelli T, Russolillo N, et al.

    American journal of surgery 2021; (222(3)):599-605 doi:10.1016/j.amjsurg.2021.01.023.

    PMID: 33546852
  12. 12

    Effect of multidisciplinary team care on patient survival in chronic hepatitis B or C hepatocellular carcinoma.

    Tseng YC, Kung PT, Peng CY, et al.

    Frontiers in oncology 2023; (13()):1251571 doi:10.3389/fonc.2023.1251571.

    PMID: 38179172

This page explains the BCLC staging system for hepatocellular carcinoma for educational purposes. Your oncologist and hepatologist are the best sources for determining your specific cancer stage and treatment options.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.